GlassScriptPhysician profile
Hari Gnanasekeram
NPI 1881867018
$277,257.10
in general payments reported to CMS, 2019-2025
36 companies · $23.67 in 2025
The $23.67 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87K · 2020: $47K · 2021: $70K · 2022: $39K · 2023: $34K · 2024: $117 · 2025: $23.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Consulting Fee: $13K · Food and Beverage: $4,392 · Travel and Lodging: $2,441 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,485.00 |
| Consulting Fee | $13,050.00 |
| Food and Beverage | $4,392.31 |
| Travel and Lodging | $2,440.63 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $113,990.04 | 2019-2023 | Jardiance, Spiriva Respimat |
| Lantheus Medical Imaging, INC. | $48,728.26 | 2019-2023 | Definity |
| Astrazeneca Pharmaceuticals LP | $47,580.47 | 2019-2022 | |
| Lilly USA, LLC | $17,152.88 | 2019-2023 | Jardiance, Mounjaro, Trulicity |
| Novo Nordisk INC | $16,514.00 | 2019-2023 | Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $9,362.75 | 2021-2023 | Nexletol |
| Biotronik INC. | $7,339.12 | 2019-2023 | Biomonitor |
| Janssen Pharmaceuticals, INC | $3,272.88 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $3,100.39 | 2019-2024 | Watchman Flx, Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $2,282.22 | 2019-2023 | Camzyos, Eliquis |
| Amgen INC. | $1,598.86 | 2019-2023 | Repatha |
| Medtronic, INC. | $1,463.14 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $933.48 | 2019-2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $777.59 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $637.02 | 2021-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $559.76 | 2019-2023 | |
| Impulse Dynamics (USA) INC. | $322.58 | 2022 | |
| Abiomed | $300.86 | 2021-2023 | Impella |
| Medtronic Vascular, INC. | $287.01 | 2019 | |
| Sanofi-Aventis U.S. LLC | $248.42 | 2019-2023 | |
| Philips North America LLC | $123.26 | 2022-2025 | Holter |
| Corcept Therapeutics | $95.49 | 2023 | Korlym |
| Regeneron Healthcare Solutions, INC. | $84.26 | 2019 | |
| Biosense Webster, INC. | $80.24 | 2022-2023 | Octaray Mapping Catheter, Carto 3 |
| Merck Sharp & Dohme LLC | $71.99 | 2021-2023 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $63.76 | 2019 | |
| Daiichi Sankyo INC. | $55.98 | 2022-2023 | Injectafer |
| Altathera Pharmaceuticals LLC | $48.88 | 2022-2023 | Sotalol Hydrochloride |
| Amarin Pharma, INC. | $40.95 | 2021-2022 | |
| Convatec INC. | $37.88 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $20.92 | 2023 | Arcalyst |
| Akcea Therapeutics, INC. | $18.19 | 2020 | |
| Edwards Lifesciences Corporation | $16.70 | 2022 | |
| Astellas Pharma US INC | $16.53 | 2021 | |
| Abbott Laboratories | $16.32 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hari Gnanasekeram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.